Edgestream Partners, L.P. Intra Cellular Therapies, Inc. Transaction History
Edgestream Partners, L.P.
- $2.23 Billion
- Q3 2024
A detailed history of Edgestream Partners, L.P. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 54,629 shares of ITCI stock, worth $4.66 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
54,629Holding current value
$4.66 Million% of portfolio
0.18%Shares
5 transactions
Others Institutions Holding ITCI
# of Institutions
377Shares Held
84.1MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$821 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$539 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$451 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$328 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$260 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.05B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...